Email ID
Sign me in automatically next time
Won't be 'same ole, same ole' for ODAC at Perjeta meeting

When the FDA's Oncologic Drugs Advisory Committee (ODAC) meets on 12 September to review the supplemental biologics license application (sBLA) for Genentech's Perjeta (pertuzumab), a humanized...
09 August 2013
Donna Young

Please Login to read the full article.
20 January 2016
PGA National, Palm Beach Gardens, FL
© 2015 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36